Literature DB >> 8293724

Identification of genetic defect of an epilepsy: strategies for therapeutic advances.

J O McNamara1.   

Abstract

Advances in molecular genetics and molecular biology are transforming the biology of human disease. Cures for diseases previously refractory to all treatments have become the reality for some disorders and the legitimate promise for others. In the case of the epilepsies, identification of mutant genes underlying familial epilepsies may lead to a new pharmacology, through the development of in vitro expression systems permitting rapid search for novel drugs, creation of highly specific animal models based on expression of the precise mutation, and correction of disease phenotype by introducing novel and highly specific genetic information into the person with epilepsy.

Entities:  

Mesh:

Year:  1994        PMID: 8293724     DOI: 10.1111/j.1528-1157.1994.tb05929.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  3 in total

Review 1.  Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging.

Authors:  L P Mark; R W Prost; J L Ulmer; M M Smith; D L Daniels; J M Strottmann; W D Brown; L Hacein-Bey
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

2.  Anticonvulsant enaminones depress excitatory synaptic transmission in the rat brain by enhancing extracellular GABA levels.

Authors:  Samuel B Kombian; Ivan O Edafiogho; Kethireddy V V Ananthalakshmi
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

3.  Evaluation of anticonvulsant actions of dibromophenyl enaminones using in vitro and in vivo seizure models.

Authors:  Mohamed G Qaddoumi; Kethireddy V V Ananthalakshmi; Oludotun A Phillips; Ivan O Edafiogho; Samuel B Kombian
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.